National Eye Institute - Eye Disease Prevalence Study Group
•
The Baltimore Eye Survey, Baltimore, MD: James M. Tielsch, Alfred Sommer, Joanne Katz, Harry A. Quigley
•
The Barbados Eye Studies, Barbados, West Indies: M. Cristina Leske, Suh-Yuh Wu, Barbara Nemesure, Anselm Hennis, Leslie Hyman, Andrew Schachat
•
The Beaver Dam Eye Study, Beaver Dam, WI: Barbara E.K. Klein, Ronald Klein, Kristine E. Lee, Scot E. Moss, Sandra C. Tomany
•
The Blue Mountains Eye Study, Sydney, New South Wales, Australia: Paul Mitchell, Jie Jin Wang, Elena Rochtchina, Wayne Smith, Robert G. Cumming, Karin Attebo, Jai Panchapakesan, Suriya Foran
•
The Melbourne Visual Impairment Project, Melbourne, Australia: Hugh R. Taylor, Cathy McCarty, Bickol Mukesh, LeAnn M. Weih, Patricia M. Livingston, Mylan Van Newkirk, Cara L. Fu, Peter Dimitrov, Matthew Wensor
•
Proyecto Vision Evaluation Research, AZ: Sheila K. West, Beatriz Muñoz, Jorge Rodriguez (deceased), Aimee T. Broman, Daniel Finklestein, Robert Snyder
•
The Rotterdam Eye Study, Rotterdam, the Netherlands: Paulus T.V.M. de Jong, Johannes R. Vingerling, Roger C.W. Wolfs, Caroline C.W. Klaver, Albert Hofman, Redmer van Leeuwen, M. Kamran Ikram, Simone de Voogd
•
The Salisbury Eye Evaluation Project, Salisbury, MD: Sheila West, Gary Rubin, Karen Bandeen Roche, Beatriz Muñoz, Kathy Turano, Oliver D. Schein, Donald Duncan
• Forme “non visive” > 55 anni 34%
• Forme con conseguenze visive
• 60-70 anni = 12%
• 70-80 anni 35%
• > 90 anni 60%
SMD-FORME CLINICHE 
• Predisposizione genetica
• Fase senza alterazioni visive à drusen
• Fase con riduzione visiva (mono / bilaterale)
A) SECCA
B) UMIDA